$CALC
CalciMedica, Inc.

2021 Q4 Form 10-K Financial Statement

#000156459022009728 Filed on March 11, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.433M $17.04M $3.690M
YoY Change 20.14% 92.15% -46.69%
% of Gross Profit
Research & Development $4.268M $18.90M $5.490M
YoY Change -22.26% -9.82% -82.05%
% of Gross Profit
Depreciation & Amortization $136.0K $519.0K $120.0K
YoY Change 13.33% 31.39% -25.0%
% of Gross Profit
Operating Expenses $8.701M $35.95M $9.180M
YoY Change -5.22% 20.5% -75.52%
Operating Profit -$35.95M
YoY Change 20.5%
Interest Expense $26.00K $126.0K $20.00K
YoY Change 30.0% -10.0% -94.91%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$8.675M -$35.82M -$9.150M
YoY Change -5.19% 30.12% -75.29%
Income Tax
% Of Pretax Income
Net Earnings -$8.675M -$35.82M -$9.150M
YoY Change -5.19% 30.11% -75.29%
Net Earnings / Revenue
Basic Earnings Per Share -$1.69
Diluted Earnings Per Share -$406.6K -$1.690M -$430.8K
COMMON SHARES
Basic Shares Outstanding 21.20M
Diluted Shares Outstanding 21.20M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.67M $63.67M $95.00M
YoY Change -32.98% -32.98%
Cash & Equivalents $13.36M $13.36M $33.42M
Short-Term Investments $50.31M $50.31M $61.60M
Other Short-Term Assets $1.353M $3.387M $1.463M
YoY Change -7.52% -19.36%
Inventory
Prepaid Expenses $1.866M $2.140M
Receivables
Other Receivables
Total Short-Term Assets $67.08M $67.08M $99.24M
YoY Change -32.41% -32.38% 173.61%
LONG-TERM ASSETS
Property, Plant & Equipment $1.981M $1.981M $1.946M
YoY Change 1.8% 4.26% -1.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $29.00K $29.00K $600.0K
YoY Change -95.17% -95.17%
Total Long-Term Assets $2.010M $2.010M $2.554M
YoY Change -21.3% -22.69% -41.81%
TOTAL ASSETS
Total Short-Term Assets $67.08M $67.08M $99.24M
Total Long-Term Assets $2.010M $2.010M $2.554M
Total Assets $69.09M $69.09M $101.8M
YoY Change -32.13% -32.13% 150.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $527.0K $527.0K $2.513M
YoY Change -79.03% -78.92% -45.79%
Accrued Expenses $304.0K $2.582M $1.356M
YoY Change -77.58% -30.22% -41.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.057M $4.057M $6.997M
YoY Change -42.02% -42.04% -42.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.000K $8.000K $0.00
YoY Change
Total Long-Term Liabilities $8.000K $8.000K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.057M $4.057M $6.997M
Total Long-Term Liabilities $8.000K $8.000K $0.00
Total Liabilities $4.065M $4.065M $7.008M
YoY Change -41.99% -41.93% -42.8%
SHAREHOLDERS EQUITY
Retained Earnings -$169.2M -$133.4M
YoY Change 26.86% 26.01%
Common Stock $234.2M $228.2M
YoY Change 2.66% 7824.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $65.02M $65.02M $94.79M
YoY Change
Total Liabilities & Shareholders Equity $69.09M $69.09M $101.8M
YoY Change -32.13% -32.13% 150.35%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$8.675M -$35.82M -$9.150M
YoY Change -5.19% 30.11% -75.29%
Depreciation, Depletion And Amortization $136.0K $519.0K $120.0K
YoY Change 13.33% 31.39% -25.0%
Cash From Operating Activities -$8.955M -$31.50M -$9.770M
YoY Change -8.34% -1.76% -52.48%
INVESTING ACTIVITIES
Capital Expenditures -$4.000K $488.0K -$820.0K
YoY Change -99.51% -52.3% 203.7%
Acquisitions
YoY Change
Other Investing Activities $10.79M $11.24M -$61.64M
YoY Change -117.5% -127.06% 207.89%
Cash From Investing Activities $10.79M $10.75M -$62.46M
YoY Change -117.27% -125.26% 207.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 81.00K 695.0K 10.68M
YoY Change -99.24% -99.25% -80.53%
NET CHANGE
Cash From Operating Activities -8.955M -31.50M -9.770M
Cash From Investing Activities 10.79M 10.75M -62.46M
Cash From Financing Activities 81.00K 695.0K 10.68M
Net Change In Cash 1.912M -20.05M -61.55M
YoY Change -103.11% -214.28% -539.02%
FREE CASH FLOW
Cash From Operating Activities -$8.955M -$31.50M -$9.770M
Capital Expenditures -$4.000K $488.0K -$820.0K
Free Cash Flow -$8.951M -$31.99M -$8.950M
YoY Change 0.01% -3.32% -55.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-27531000
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0084
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0025
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.87
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.88
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0112
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0053
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Redwood City, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13364000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33418000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
50306000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
61615000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3408000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4207000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
67078000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
99240000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1981000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1946000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
29000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
608000
CY2021Q4 us-gaap Assets
Assets
69088000
CY2020Q4 us-gaap Assets
Assets
101794000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
527000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2513000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
304000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1356000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3226000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3128000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4057000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6997000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
11000
CY2021Q4 us-gaap Liabilities
Liabilities
4065000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Liabilities
Liabilities
7008000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21199291
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
695000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5375000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-7000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21357773
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21357773
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20979265
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20979265
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
234225000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
228155000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169188000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-133367000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65023000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
94786000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69088000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101794000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18903000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20962000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17044000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8870000
CY2021 us-gaap Operating Expenses
OperatingExpenses
35947000
CY2020 us-gaap Operating Expenses
OperatingExpenses
29832000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-35947000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-29832000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
126000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
143000
CY2020 gray Change In Fair Value Of Preferred Stock Tranche Obligation
ChangeInFairValueOfPreferredStockTrancheObligation
2158000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-35821000
CY2020 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
7189000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34720000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-12000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35833000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27538000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-102954000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
77000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1788000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-27531000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-35821000
CY2020 us-gaap Profit Loss
ProfitLoss
-27531000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
5375000
CY2021 us-gaap Depreciation
Depreciation
519000
CY2020 us-gaap Depreciation
Depreciation
395000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1788000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65023000
CY2021 us-gaap Profit Loss
ProfitLoss
-35821000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-12000
CY2020 gray Change In Fair Value Of Preferred Stock Tranche Obligation
ChangeInFairValueOfPreferredStockTrancheObligation
2158000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-58000
CY2021 gray Increase Decrease In Prepaid Expenses And Other Current And Noncurrent Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets
-1378000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2052000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1052000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
95000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31500000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
488000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
94570000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
61637000
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
105809000
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
20100000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10751000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
96255000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
695000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
77000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4160000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
695000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
92172000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20054000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17548000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33418000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15870000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13364000
CY2020 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
131363000
CY2021 gray Property And Equipment Purchases Included In Accounts Payable
PropertyAndEquipmentPurchasesIncludedInAccountsPayable
115000
CY2020 gray Property And Equipment Purchases Included In Accounts Payable
PropertyAndEquipmentPurchasesIncludedInAccountsPayable
49000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169200000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2140000
CY2021Q4 gray Prepaid Clinical And Research Expenses Current
PrepaidClinicalAndResearchExpensesCurrent
168000
CY2020Q4 gray Prepaid Clinical And Research Expenses Current
PrepaidClinicalAndResearchExpensesCurrent
6000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to accrued research and development expenses, contingent </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">milestone payments, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other long-lived assets,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock-based compensation</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the valuation of deferred tax assets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and adjusts those estimates and assumptions when facts and circumstances dictate.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s results can also be affected by economic, political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest, changes in regulatory laws and monetary exchange rates, and government fiscal policies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities, the Company could be adversely affected by civil, criminal, regulatory or administrative actions, claims, or related proceedings.</p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-balance Sheet Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents and available-for-sale marketable securities. The Company’s investment policy includes guidelines regarding the quality of the financial institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company may invest in money market funds, U.S. Treasury securities, corporate debt, U.S. government-related agency securities, commercial paper and certificates of deposit. At December 31, 2021 and 2020, the Company’s cash and cash equivalents were held in financial institutions that management believes are creditworthy. These deposits may exceed federally insured limits. The Company has not experienced any losses historically in these accounts and believes it is not exposed to significant credit risk in its cash and cash equivalents. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</p>
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3408000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 gray Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
21000
CY2020Q4 gray Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
598000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
13149000
CY2021Q4 gray Short Term Investment Fair Value Disclosure
ShortTermInvestmentFairValueDisclosure
50306000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
63455000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
31676000
CY2020Q4 gray Short Term Investment Fair Value Disclosure
ShortTermInvestmentFairValueDisclosure
61615000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
93291000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3634000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3080000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1653000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1134000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1981000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1946000
CY2021 us-gaap Depreciation
Depreciation
519000
CY2020 us-gaap Depreciation
Depreciation
395000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1866000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4207000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1353000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1463000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2278000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2302000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
461000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
425000
CY2021Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
8000
CY2020Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
27000
CY2021Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
479000
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
374000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3226000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3128000
CY2021Q4 gray Contractual Termination Obligation
ContractualTerminationObligation
3700000
CY2021 gray Unpaid Cancellation And Other Related Costs
UnpaidCancellationAndOtherRelatedCosts
0
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
527000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
205000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
732000
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
142150096
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
117809883
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
131363000
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
148592000
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
The holders of Series C Preferred are entitled to elect one director of the Company; the holders of Series B Preferred are entitled to elect three directors of the Company; the holders of Series A-2 Preferred, are entitled to elect one director; the holders of common stock are entitled to elect one director; and holders of common stock and any other class or series of voting stock, exclusively and voting together as a single class on an as-converted basis, are entitled to elect one director. Holders of Series A Preferred are not entitled to a director of the Company.
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2756102
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.28
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
57090000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1649500
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.74
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
353508
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.97
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
274696
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.52
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3777398
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.58
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
41967000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1705619
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.24
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
41967000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2500000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
113000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4000000.0
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1400000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
6.06
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2.43
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.006
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.85
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.013
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.72
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.90
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5375000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1788000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
15400000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.006
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.032
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.014
CY2020 gray Effective Income Tax Rate Reconciliation Mark To Market Gain Or Loss
EffectiveIncomeTaxRateReconciliationMarkToMarketGainOrLoss
0.017
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.226
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.266
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
34431000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27567000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
5408000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4887000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1408000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
748000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
41247000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33202000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41215000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33141000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
32000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
61000
CY2021Q4 gray Deferred Income Tax Liabilities Depreciation
DeferredIncomeTaxLiabilitiesDepreciation
32000
CY2020Q4 gray Deferred Income Tax Liabilities Depreciation
DeferredIncomeTaxLiabilitiesDepreciation
61000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
32000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
61000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8100000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
157400000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
23300000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1981000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1406000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
257000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
406000
CY2021 gray Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
-148000
CY2020 gray Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
169000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2090000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1981000
CY2021 gray Unrecognized Tax Benefits Income Tax Accrued Interest And Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxAccruedInterestAndPenaltiesExpense
0
CY2020 gray Unrecognized Tax Benefits Income Tax Accrued Interest And Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxAccruedInterestAndPenaltiesExpense
0
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-35821000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-27531000
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
7189000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35821000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34720000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.69
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.25
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21199291
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6618445

Files In Submission

Name View Source Status
0001564590-22-009728-index-headers.html Edgar Link pending
0001564590-22-009728-index.html Edgar Link pending
0001564590-22-009728.txt Edgar Link pending
0001564590-22-009728-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gray-10k_20211231.htm Edgar Link pending
gray-10k_20211231_htm.xml Edgar Link completed
gray-20211231.xsd Edgar Link pending
gray-20211231_cal.xml Edgar Link unprocessable
gray-20211231_def.xml Edgar Link unprocessable
gray-20211231_lab.xml Edgar Link unprocessable
gray-20211231_pre.xml Edgar Link unprocessable
gray-ex231_7.htm Edgar Link pending
gray-ex311_6.htm Edgar Link pending
gray-ex312_8.htm Edgar Link pending
gray-ex321_10.htm Edgar Link pending
gray-ex322_9.htm Edgar Link pending
gw2pguu3ddux000001.jpg Edgar Link pending
gw2pguu3ddux000002.jpg Edgar Link pending
gw2pguu3ddux000003.jpg Edgar Link pending
gw2pguu3ddux000004.jpg Edgar Link pending
gw2pguu3ddux000005.jpg Edgar Link pending
gw2pguu3ddux000006.jpg Edgar Link pending
gw2pguu3ddux000007.jpg Edgar Link pending
gw2pguu3ddux000008.jpg Edgar Link pending
gw2pguu3ddux000009.jpg Edgar Link pending
gw2pguu3ddux000010.jpg Edgar Link pending
gw2pguu3ddux000011.jpg Edgar Link pending
gw2pguu3ddux000012.jpg Edgar Link pending
gw2pguu3ddux000013.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending